본문 바로가기
bar_progress

Text Size

Close

Samsung Biologics Achieves Integrated 'A Grade' in ESG Comprehensive Evaluation for Two Consecutive Years

Samsung Biologics Achieves Integrated 'A Grade' in ESG Comprehensive Evaluation for Two Consecutive Years Samsung Biologics Plant 3 exterior view. [Photo by Samsung Biologics]

[Asia Economy Reporter Lee Gwan-joo] Samsung Biologics announced on the 24th that it received an overall 'A grade' for the second consecutive year by achieving A grade or higher in all categories in the '2022 ESG Evaluation and Rating Announcement for Listed Companies' released by the Korea Corporate Governance Service (KCGS).


The ESG evaluation by the Korea Corporate Governance Service is a representative domestic ESG evaluation index that assesses the sustainability of about 1,000 listed companies in Korea based on environmental management, social responsibility management, and governance. This year, the evaluation criteria were completely revised, significantly increasing the difficulty level.


Samsung Biologics published reports reflecting its ESG promotion achievements and improved vulnerable areas, receiving an A+ in social responsibility management, and A grades in environmental management and governance, thereby obtaining an integrated 'A grade' again this year.


In particular, in the environmental category, the company was highly evaluated for presenting greenhouse gas reduction performance and systematic management of environmental data; in the social category, for mitigating supplier risks and conducting regular information security training; and in the governance category, for enhancing board composition and proactively managing potential risks.


John Rim, President of Samsung Biologics, said, "Samsung Biologics' consecutive excellent results in leading domestic and international ESG evaluations demonstrate that the company's ESG management is recognized worldwide. We will continue to take the lead to ensure that sustainable management efforts become established throughout the biopharmaceutical industry."


Meanwhile, Samsung Biologics has also been recognized domestically and internationally for its ESG management capabilities, having received the Gold grade, awarded only to the top 5% of companies, in the ESG evaluation by EcoVadis, a global sustainability assessment organization, earlier in September.


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top